Worldwide SD market Is Projected To Gain a 25% Overall Compound Annual Growth Rate (CAGR) To Reach More Than $5.4B by 2007

(PRWEB) November 18, 2004

Our report provides strategic analysis of the market for major sexual dysfunction (SD) categories for women and men.


Women

requirements include dysfunction of desire, arousal, or orgasm, or pain during sex.


Men

conditions include premature ejaculation, erectile dysfunction and other male disorders.

The report examines the factors influencing the market for male and female SD conditions, critically evaluates emerging therapeutic SD, and provides an in-depth analysis on the expanded indications that affect the pricing practices and the influence and perceptions.

The global SD is expected to acquire a 25% overall growth rate (CAGR) to over $ 5.4B in 2007.


I.

Summary

A.

Overview

B.

Scope

C. Definition

D. Current treatments

1. Therapeutics

E. Prevalence sexual dysfunction

F. Sexual Dysfunction Market Revenue (2002E – 2007E)

1. World

2. United States

G. Segment revenues (2002E and 2007E)

1. World

2. United States

H. Competitive environment (2002E and 2007E)

1. World

2. United States

3. Key players

I. Emerging Therapeutics

1. Sales forecasts in the world 2007E

2. United States has projected sales in 2007E

3. Compounds in development

4. Competitive landscape

J. Market Influencing Factors

1. Factors Influencing Price-

2. Volume-Influencing factors

K. Strategic analysis

1. Evaluate the industry landscape in the short term

2. Identify market opportunities

3. Form of policy recommendations

II. Objectives and methodology

A.

Objectives and Scope of Report

1. Goals

2. Scope

B.

Methodology

1. Sexual Dysfunction – Prevalence Models

2. Construction of the market model

3. Emerging Products Benchmarking

a.

Evaluation Criteria

b.

Assumptions and justification

C. Key Players and Strategic Analysis

1. Clinical assessment

2. Market Position

3. Comparison parameters

a.

comparison 2002E

b.

Matrix positioning 2002E

D. Data Collection

1. Primary Sources

2. Secondary Sources

E. Strategic Recommendations

1. External analysis

2. Development Strategy

III. Overview sexual dysfunction clinic

A.

Definition

1. Female sexual dysfunction

a.

dysfunction of Desire

b.

arousal dysfunction

c. Dysfunction orgasm

d. Experience of pain during sex

2. Male sexual dysfunction

a.

premature ejaculation

b.

Erectile Dysfunction

c. Other disorders Man

B.

Physiology

1. Female

a.

Genitals

b.

sexual response cycle

2. Man

a.

Genitals

b.

sexual response cycle

C. Causes and Risk Factors

1. Female Sexual Dysfunction Risk Factors

2. Male Sexual Dysfunction Risk Factors

3. Causes of Pharmacology of low sexual desire

D. Diagnosis of sexual dysfunction

1. Psychological diagnosis

2. Female physiological diagnosis

3. Diagnostic Physiological Human

E. Prevalence sexual dysfunction

1. World

2. United States

3. Model Assumptions

F. Current treatments

1. Therapeutics

a.

drugs currently listed

i. Prostaglandins

ii. Phospodiesterase inhibitors

iii. Dopamine agonists

iv. Endogenous hormones

c. Adrenergic

b. Off-label drug

i.

Hormone replacement therapy

ii. Selective inhibitors of serotonin reuptake inhibitors (SSRIs)

2. Other courses of treatment

a.

Herbal Remedies

b.

Devices

c. Psychotherapy

G. Emerging Treatments

IV. Market sexual dysfunction

A. Sexual Dysfunction

market revenues (2002E – 2007E)

1. World

2. United States

B.

income segment (2002E and 2007E)

1. World

2. United States

C. Competitive environment (2002E and 2007E)

1. World

2. United States

3. Key players

a. Assessment

position – 2002E

b. Assessment

position – 2007E

4. Analysis of existing competitors

D. Sales of high (2002E – 2007E)

1. World

2. United States

E. Emerging Therapeutics

1. Sales forecasts in the world 2007E

2. United States has projected sales in 2007E

F. Construction of the market model

V. Emerging Therapeutics sexual dysfunction

A.

Overview

B. Products

analysis methodology development

C. Leading products in development

1. Compounds in Phase III or later

2. Compounds in Phase II

3. Compounds in Phase I

4. Composed of pre-clinical development

D. The categories of products in Phase III or later

E. Comparative analysis of emerging products

1. Process Benchmarking

2. Competitive landscape

3. Ranking Overview of Emerging Therapeutics sexual dysfunction

4. Assessment of sexual dysfunction Therapeutics

5. Test data key drugs in development

6. Highlights potential attractiveness of the market for drugs in development

F. Company Analysis

VI. Market Influencing Factors

A.

Overview

B. Factors affecting the market

sexual dysfunction

1. Factors Influencing Price-

a. Refund

b.

Competitive Environment

c. Product Enhancements

d. Inflation

2. Volume-Influencing factors

a. Sexual Dysfunction

population growth

b.

Outreach

c. Marketing effort

d. Formulation

VII. Strategic analysis

A.

Overview

B.

evaluate the landscape industry in the short term

1. Increase competition in the market for TMS

2. The combination of an underdeveloped market with products emerging EHR

3. Strong patent protection and exclusivity

4. Multiple access points from the patient for a growing population sexual dysfunction

C. Identify market opportunities

1. Current unmet needs

a.

Female Sexual Dysfunction

b.

premature ejaculation

2. Improvement of current treatments

a.

Reduced side effects

b.

Enhanced action of existing drugs

c. Improved therapies by injection of prostaglandin

d. Reformulation and a combination of current treatments

D. Form of policy recommendations

1. Optimal pricing strategies

a.

Market Entry

b. Annual Increases

2. Increase the volume Strategies

a. Improved diagnostic

b.

General Public Education

c. The promotion by doctors

d. Direct-to-Consumer (DTC) Marketing

e. Offers reimbursement form to promote sales

Appendix: Definitions and Acronyms

A.

Definitions

B.

Acronyms

For more information visit http://www.researchandmarkets.com/reports/c9425

Laura Wood

Senior Manager

Research and Markets

press@researchandmarkets.com

Fax: +353 1 4100 980

Find More Premature Ejaculation Press Releases

This entry was posted in Premature Ejaculation and tagged , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

Notify me of followup comments via e-mail. You can also subscribe without commenting.